A major review challenges a long-standing strategy in Alzheimer’s research, suggesting that removing a hallmark brain protein may not lead to meaningful improvements for patients.
A major new Cochrane review is challenging one of the most influential ideas in Alzheimer’s treatment: that clearing amyloid beta from the brain will meaningfully slow the disease.
The review found that anti-amyloid drugs can remove amyloid plaques, but that change does not appear to translate into a noticeable clinical benefit for patients. At the same time, these treatments may increase the risk of brain swelling and bleeding.
Amyloid beta is a protein that builds up in the brains of people with Alzheimer’s disease, often before symptoms appear. While this buildup has long been linked to the disease, its exact role in driving progression remains unclear. Many treatments have aimed to remove these proteins, based on the idea that clearing them could slow or prevent cognitive decline.
The review analyzed results from 17 clinical trials involving 20,342 participants. These studies focused on people with mild cognitive impairment or early-stage dementia caused by Alzheimer’s disease. Supporters of anti-amyloid therapies have argued that earlier intervention might improve outcomes, before significant damage occurs.
Absolute effects “well below clinical threshold”
Overall, researchers found that these drugs had little to no impact on cognitive decline or the severity of dementia. Any measured effects were minimal and did not meet accepted standards for a meaningful clinical improvement.
“Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” says lead author Francesco Nonino, neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna, Italy. “There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect. While early trials showed results that were statistically significant, it is important to distinguish between this and clinical relevance. It is common for trials to find statistically significant results that do not translate into a meaningful clinical difference for patients.”
The analysis also found an increased risk of brain swelling and bleeding among patients taking these medications. In many cases, these issues were detected through imaging scans and did not produce obvious symptoms. However, the long-term effects remain uncertain because symptom reporting varied across the trials.
Future research should focus on other pathways
Based on the available evidence, the authors conclude that continuing to target amyloid beta is unlikely to produce clear benefits for patients.
Although these treatments can reduce amyloid levels in the brain, this change does not lead to meaningful improvements in symptoms or disease progression. The researchers recommend shifting attention to other biological mechanisms, several of which are already under investigation.
“I see Alzheimer’s patients in my clinic every week and I wish I had an effective treatment to offer them,” says senior author Edo Richard, Professor of Neurology at Radboud University Medical Centre. “Existing approved drugs offer some benefit for some patients, but there remains a high unmet need for more effective treatments. Sadly, anti-amyloid drugs do not offer this and bring additional risks. Given the absence of correlation between amyloid removal and clinical benefit, we need to explore other pathways to help address this devastating disease.”
Reference: “Amyloid‐beta‐targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease” by Francesco Nonino, Silvia Minozzi, Luisa Sambati, Cinzia Del Giovane, Elisa Baldin, Maria Chiara Bassi, Claudia De Santis, Marien Gonzalez-Lorenzo, Luca Vignatelli, Graziella Filippini and Edo Richard, 16 April 2026, Cochrane Database of Systematic Reviews.
DOI: 10.1002/14651858.CD016297
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.